MedTrace Logo

Effect of Low-Dose Caffeine on Performance in Elite Sitting Volleyball Players

NCT07056231 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2025-07-09

No results posted yet for this study

Summary

Background: Sitting volleyball is a sport that relies primarily on upper body strength and anaerobic capacity. In critical in-game skills such as serve and spike, factors such as speed-endurance time and impact power play a decisive role in performance. There are limited studies in the literature examining the effects of low-dose caffeine consumption on these skills. The effects of ergogenic supplements in Paralympic sports have not been sufficiently investigated, and the potential benefits of caffeine on serve and spike performance in sitting volleyball players remain unclear. Purpose: The main purpose of this research was to determine the effects of low-dose caffeine (3 mg/kg) consumption on the serve speed, spike speed and Speed-Endurance performances of elite-level sitting volleyball players. Method: The study was designed using a randomized, double-blind, balanced, and crossover experimental design. 13 elite male athletes from the 2024 Paravolley European Champion Sitting Volleyball Men's National Team participated in the study. Participants were evaluated for serve speed, spike speed, and speed-endurance performances in both 3 mg/kg caffeine (CAF) and placebo (PLA) conditions.

Conditions

  • Caffeine
  • Physical Endurance
  • Muscle Strength
  • Paralympic Athletes

Interventions

DIETARY_SUPPLEMENT

Caffeine

A single oral dose of 3 mg of caffeine per kilogram of body weight form approximately 60 minutes before performance testing. Supplied by Oxford Vitality, ISO-certified.

DIETARY_SUPPLEMENT

Placebo

polydextrose used as Placebo

Sponsors & Collaborators

  • Ulaç Can YILDIRIM

    lead OTHER

Principal Investigators

  • Ulas C Yildirim · sinop university faculty of sport sciences

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-05
Primary Completion
2025-03-11
Completion
2025-03-12

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07056231 on ClinicalTrials.gov